Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery.

Robertson CR, Scholl EA, Pruess TH, Green BR, White HS, Bulaj G.

J Med Chem. 2010 Feb 25;53(4):1871-5. doi: 10.1021/jm9018349.

2.

Neuropeptides in learning and memory processes with focus on galanin.

Ogren SO, Kuteeva E, Elvander-Tottie E, Hökfelt T.

Eur J Pharmacol. 2010 Jan 10;626(1):9-17. doi: 10.1016/j.ejphar.2009.09.070. Epub 2009 Oct 18. Review.

PMID:
19837050
3.

Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors.

Picciotto MR, Brabant C, Einstein EB, Kamens HM, Neugebauer NM.

Brain Res. 2010 Feb 16;1314:206-18. doi: 10.1016/j.brainres.2009.08.033. Epub 2009 Aug 20. Review.

4.

Pilocarpine vs. lithium-pilocarpine for induction of status epilepticus in mice: development of spontaneous seizures, behavioral alterations and neuronal damage.

Müller CJ, Bankstahl M, Gröticke I, Löscher W.

Eur J Pharmacol. 2009 Oct 1;619(1-3):15-24. doi: 10.1016/j.ejphar.2009.07.020. Epub 2009 Jul 24.

PMID:
19632220
5.

A novel GalR2-specific peptide agonist.

Runesson J, Saar I, Lundström L, Järv J, Langel U.

Neuropeptides. 2009 Jun;43(3):187-92. doi: 10.1016/j.npep.2009.04.004. Epub 2009 May 20.

PMID:
19467704
6.

Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models.

White HS, Scholl EA, Klein BD, Flynn SP, Pruess TH, Green BR, Zhang L, Bulaj G.

Neurotherapeutics. 2009 Apr;6(2):372-80. doi: 10.1016/j.nurt.2009.01.001.

7.

Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues.

Zhang L, Robertson CR, Green BR, Pruess TH, White HS, Bulaj G.

J Med Chem. 2009 Mar 12;52(5):1310-6. doi: 10.1021/jm801397w.

8.

Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs.

Wasterlain CG, Chen JW.

Epilepsia. 2008 Dec;49 Suppl 9:63-73. doi: 10.1111/j.1528-1167.2008.01928.x. Review.

9.

Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities.

Bulaj G, Green BR, Lee HK, Robertson CR, White K, Zhang L, Sochanska M, Flynn SP, Scholl EA, Pruess TH, Smith MD, White HS.

J Med Chem. 2008 Dec 25;51(24):8038-47. doi: 10.1021/jm801088x.

PMID:
19053761
10.

Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease.

Crawley JN.

Cell Mol Life Sci. 2008 Jun;65(12):1836-41. doi: 10.1007/s00018-008-8158-3. Review.

11.

Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective?

Counts SE, Perez SE, Mufson EJ.

Cell Mol Life Sci. 2008 Jun;65(12):1842-53. doi: 10.1007/s00018-008-8159-2. Review.

12.

Post-infarct cardiac sympathetic hyperactivity regulates galanin expression.

Ewert TJ, Gritman KR, Bader M, Habecker BA.

Neurosci Lett. 2008 May 9;436(2):163-6. doi: 10.1016/j.neulet.2008.03.012. Epub 2008 Mar 18.

13.

N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.

Wickenden AD, Krajewski JL, London B, Wagoner PK, Wilson WA, Clark S, Roeloffs R, McNaughton-Smith G, Rigdon GC.

Mol Pharmacol. 2008 Mar;73(3):977-86. Epub 2007 Dec 18.

14.

Galanin gene transfer curtails generalized seizures in kindled rats without altering hippocampal synaptic plasticity.

Kanter-Schlifke I, Toft Sørensen A, Ledri M, Kuteeva E, Hökfelt T, Kokaia M.

Neuroscience. 2007 Dec 19;150(4):984-92. Epub 2007 Sep 29.

PMID:
17988802
15.

The brain galanin receptors: targets for novel antidepressant drugs.

Lu X, Sharkey L, Bartfai T.

CNS Neurol Disord Drug Targets. 2007 Jun;6(3):183-92. Review.

PMID:
17511615
17.

Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: The effects of subtype-selective agonists and the role of G-protein-mediated signaling.

Mazarati A, Lundström L, Sollenberg U, Shin D, Langel U, Sankar R.

J Pharmacol Exp Ther. 2006 Aug;318(2):700-8. Epub 2006 May 12.

18.

Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction?

Holmes A, Picciotto MR.

CNS Neurol Disord Drug Targets. 2006 Apr;5(2):225-32. Review.

PMID:
16611095
19.

Treatment of experimental status epilepticus in immature rats: dissociation between anticonvulsant and antiepileptogenic effects.

Suchomelova L, Baldwin RA, Kubova H, Thompson KW, Sankar R, Wasterlain CG.

Pediatr Res. 2006 Feb;59(2):237-43.

PMID:
16439585
20.

The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors.

El Bahh B, Balosso S, Hamilton T, Herzog H, Beck-Sickinger AG, Sperk G, Gehlert DR, Vezzani A, Colmers WF.

Eur J Neurosci. 2005 Sep;22(6):1417-30.

PMID:
16190896

Supplemental Content

Support Center